Abstracts tagged "Lupus nephritis"

Abstract Number: 2570 • 2017 ACR/ARHP Annual Meeting
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Naomi I. Maria¹, Megan Woods², Shani Martinez³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ³Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis. Increasing evidence suggests the crucial role of cell-specific…
Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 99 • 2017 Pediatric Rheumatology Symposium
PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS
Sangeeta Sule¹, Sarah Joo² and Meredith Atkinson², ¹Pediatrics, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Cardiovascular disease (CV dz) is common in SLE and lupus nephritis (LN), but premature atherosclerosis risk does not appear to be linked to classic…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 92 • 2017 Pediatric Rheumatology Symposium
Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
Maria Pereira¹, Eyal Muscal², Marietta DeGuzman³, Anna Carmela Sagcal-Gironella⁴ and Scott E. Wenderfer⁵, ¹Immunology, Allergy & Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Treatment guidelines for childhood-onset class V membranous lupus nephritis (MLN) have not yet been established. The addition of mycophenolate mofetil (MMF) has shown improvement…
Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…
Abstract Number: 1396 • 2016 ACR/ARHP Annual Meeting
Cognitive Function in Children with SLE Nephritis: A Cross-Sectional Comparison to Children with Other Glomerular Chronic Kidney Diseases
Andrea Knight^1,2,3, Matthew Matheson⁴, Susan Furth⁵, Brad Warady⁶, Stephen Hooper⁷ and Amy Kogon⁸, ¹Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁵Division of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Division of Nephrology, Children's Mercy Hospital, Kansas City, MO, ⁷Department of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, NC, ⁸Division of Nephrology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Children with lupus nephritis (LN) are at risk for cognitive impairment due to effects on the brain from systemic inflammation and from potential effects…
Abstract Number: 1835 • 2016 ACR/ARHP Annual Meeting
Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway
Ou Jin, Chengcheng Hou, Qiuxia Li, Xi Zhang, Qiujing Wei, Hongyue Huang, Mingli Qiu and Jieruo Gu, Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China
Background/Purpose: () - -the Immunohistochemistry was to observe the expression of NOD2 in renal biopsies eal-time uantitative olymerase hain eactionPCR was used to detect the level of…
Abstract Number: 2061 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Yehuda Shoenfeld¹, Tomer Bashi², Hadar Gershon³, Or Givol⁴, Alexander Volkov⁵, Iris Barshack⁵, Mati Fridkin⁶, Miri Blank² and Omry Koren⁷, ¹Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ²Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Sefat Medical School, Bar-Ilan University, Sefat, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Ramat Gan, Israel, ⁵Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ⁶Organic chemistry, Weizmann Institute for Sciences, Rehovot, Israel, ⁷Sefat medical school, Bar-Ilan university, Sefat, Israel
Background/Purpose: , In areas where helminths infections are common, autoimmune diseases are rare. Treatment with helminthes and their ova, improved clinical findings of inflammatory bowel…
Abstract Number: 2794 • 2016 ACR/ARHP Annual Meeting
Sustained Complete Remission in Lupus Nephritis
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The durability of renal remission might be a predictor of good long-term renal outcome and survival in patients with lupus nephritis (LN). We aimed…
Abstract Number: 2799 • 2016 ACR/ARHP Annual Meeting
Outcomes in Patients with Early and Delayed Onset Lupus Nephritis
Roaa ALJohani¹, Dafna D. Gladman¹, Jiandong Su¹ and Murray Urowitz², ¹Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare disease characteristics in patients with early and delayed onset of lupus nephritis(LN) and their outcomes after 5 years of follow-up. Methods: Patients…
Abstract Number: 2804 • 2016 ACR/ARHP Annual Meeting
Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
Eleana Ntatsaki¹, Alba Velo Garcia², Borja del Carmelo Gracia Tello Sr.³, Alan D. Salama⁴ and David A. Isenberg⁵, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), leading to end stage renal failure…
Abstract Number: 2805 • 2016 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Chee Ken Cheah¹, Shirish Sangle (Joint First Author)¹, Alina Casian², Oier Barrutia¹, Munther Khamashta¹ and David D'Cruz¹, ¹Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ²Rheumatology, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) complicates 60% of systemic lupus erythematosus (SLE) patients within 5 years of diagnosis. Glucocorticoids and disease modifying immunosuppressive drugs (IS) are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].